8-K: Cryoport Q3 Revenue Up 15%, Full-Year Guidance Raised

Cryoport, Inc. reported a 15% year-over-year revenue increase to $44.2 million for Q3 2025 and raised its full-year 2025 revenue guidance to $170-$174 million.

Summary

• Total revenue from continuing operations for Q3 2025 was $44.2 million, marking a 15% year-over-year increase.
• Commercial Cell & Gene Therapy revenue grew 36% year-over-year to $8.3 million in Q3 2025.
• Life Sciences Services revenue increased 16% year-over-year to $24.3 million, representing 55% of total revenue.
• BioStorage/BioServices revenue within Life Sciences Services rose 21% year-over-year.
• Life Sciences Products revenue grew 15% year-over-year to $20.0 million.
• Gross margin from continuing operations improved to 48.2% for Q3 2025, up from 45.5% in Q3 2024.
• Adjusted EBITDA from continuing operations improved to negative $0.6 million for Q3 2025, compared to negative $2.7 million for Q3 2024.
• The company reported a net loss of $6.9 million for Q3 2025 and a net loss attributable to common stockholders of $8.9 million, or $0.18 per share.
• Cryoport supported 19 commercial therapies and a total of 745 global clinical trials as of September 30, 2025, a net increase of 54 trials year-over-year, with 83 in Phase 3.
• Full-year 2025 revenue guidance from continuing operations was updated and raised to a range of $170.0 million to $174.0 million.
• Cash, cash equivalents, and short-term investments totaled $421.3 million as of September 30, 2025.
• The company repurchased 483,397 shares of common stock for $3.7 million during Q3 2025, with $65.9 million remaining in repurchase authorization.

Sentiment

Score: 8

Explanation: Strong revenue growth across all segments, significant improvement in adjusted EBITDA, and raised full-year guidance indicate positive operational momentum and a clear path towards profitability, despite a reported net loss. The strategic partnership and infrastructure expansion further support long-term growth.

Positives

• Strong Q3 2025 revenue growth of 15% year-over-year to $44.2 million from continuing operations.
• Significant 36% year-over-year growth in Commercial Cell & Gene Therapy revenue to $8.3 million.
• Double-digit growth across all segments: Life Sciences Services (16%), BioStorage/BioServices (21%), and Life Sciences Products (15%).
• Improved gross margin from continuing operations to 48.2% in Q3 2025 from 45.5% in Q3 2024.
• Adjusted EBITDA from continuing operations improved to negative $0.6 million in Q3 2025 from negative $2.7 million in Q3 2024, demonstrating progress towards profitability.
• Raised full-year 2025 revenue guidance to $170.0 million $174.0 million, reflecting increased confidence.
• Strong cash position with $421.3 million in cash, cash equivalents, and short-term investments.
• Expansion of global infrastructure with a new Global Supply Chain Center opened in Paris, France.
• Strategic partnership with DHL Group is anticipated to fuel growth in Life Sciences Services in EMEA and APAC.
• Successful launch of next-generation MVE dry vapor shippers with integrated Condition Monitoring Solutions.
• Customer ExCellThera received conditional marketing authorization from the European Commission for Zemcelpro, a cell therapy for blood cancer patients.
• Customer Bristol Myers Squibb received supplemental approval from the EC to expand the label of Breyanzi.

Negatives

• Reported a net loss of $6.9 million for Q3 2025.
• Adjusted EBITDA from continuing operations remains negative at $0.6 million for Q3 2025.
• Net loss attributable to common stockholders was $8.9 million, or $0.18 per share, for Q3 2025.

Risks

• Anticipated approvals and filings for new therapies or label/geographic expansions during the remainder of 2025 may be adversely impacted by the current federal government shutdown in the United States.
• Full-year 2025 guidance is dependent on current business and expectations, which may be impacted by factors outside of the company's control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions, and the effects of foreign currency fluctuations.
• The company's business could be affected by variations in cash flow, market acceptance risks, and technical development risks.
• Any disruption resulting from the DHL Transaction may adversely affect businesses and business relationships, including with employees and suppliers.

Future Outlook

Cryoport expects full-year 2025 revenue from continuing operations to be in the range of $170.0 million to $174.0 million, an increase from previous guidance. The company anticipates up to an additional 7 application filings, 1 new therapy approval, and 2 additional approvals for label/geographic expansions during the remainder of 2025. For 2026, 5 customers have Prescription Drug User Fee Act (PDUFA) dates in the first and very early second quarter, and up to 25 possible BLA/MAA filings are forecasted, with the majority being for new therapies. The strategic partnership with the DHL Group is expected to fuel growth in the Life Sciences Services business in EMEA and APAC.

Management Comments

• "Q3 was another outstanding quarter for Cryoport with 15% year-over-year growth in revenue from continuing operations."
• "During the third quarter, we continued to see strong momentum, with double-digit growth. A driver of our total Q3 revenue was from the support of commercial cell and gene therapies, which grew 36% year-over-year to $8.3 million."
• "Cryoport continues to demonstrate a visible pathway to profitability with improvements in adjusted EBITDA and a solid gross margin of 48% in Q3, while continuing to invest in our priority growth initiatives to drive long-term value."
• "With our momentum and year-to-date performance along with our strong Q3 results, we are raising our full-year revenue guidance from continuing operations to a range of $170.0 million to $174.0 million."
• "Cryoport continues to maintain competitive differentiation as the only pure-play end-to-end temperature-controlled supply chain platform that supports the largest portfolio of clinical and commercial Cell & Gene therapies."

Industry Context

Cryoport operates in the specialized and growing temperature-controlled supply chain sector for life sciences, with a strong emphasis on regenerative medicine. The reported strong growth in commercial cell and gene therapy revenue (36% YOY) indicates robust demand in this high-growth segment of the biopharmaceutical industry. The company's expansion of global infrastructure and strategic partnerships, such as with DHL, are common strategies for companies in this sector to enhance global reach and service capabilities, especially for sensitive biologics requiring precise logistics. The increase in supported clinical trials (745 total, 83 in Phase 3) reflects the broader industry's strong pipeline in advanced therapies, which Cryoport is well-positioned to support.

Comparison to Industry Standards

• The filing states that Cryoport "continues to maintain competitive differentiation as the only pure-play end-to-end temperature-controlled supply chain platform that supports the largest portfolio of clinical and commercial Cell & Gene therapies." This suggests a leading or unique position within its niche, though no specific comparable companies or projects are named for direct quantitative comparison.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong financial performance, raised guidance, improved profitability metrics, and ongoing share repurchase program.
• Customers: Enhanced service capabilities through new product launches (MVE shippers with condition monitoring, IntegriCell), expanded global infrastructure (Paris, Santa Ana), and strategic partnership with DHL, leading to more integrated and reliable supply chain solutions.
• Employees: Potential for growth and expansion with new facilities and strategic initiatives, though the DHL transaction risk mentions potential adverse effects on employees.
• Suppliers: The DHL transaction risk mentions potential adverse effects on suppliers, though the overall tone is positive for growth.

Next Steps

• Onboarding first clients for IntegriCell, with technology transfer activities nearing completion for multiple biotechnology and top 10 pharmaceutical companies.
• Advancing plans to open another Global Supply Chain Center in Santa Ana, California, targeted for late 2026.
• Leveraging the strategic partnership with DHL Group to fuel growth in Life Sciences Services in EMEA and APAC.
• Anticipate up to an additional 7 BLA/MAA filings, 1 new therapy approval, and 2 label/geographic expansions during the remainder of 2025.
• 5 customers have PDUFA dates in Q1 and early Q2 2026.
• Forecasting up to 25 possible BLA/MAA filings in 2026, with the majority being for new therapies.
• Filing of Quarterly Report on Form 10-Q for Q3 2025 with the SEC on November 6, 2025.

Key Dates

Recommendation

The company demonstrated strong Q3 2025 financial performance with double-digit revenue growth across all segments, particularly in the high-growth commercial cell and gene therapy sector. The significant improvement in adjusted EBITDA, coupled with raised full-year revenue guidance, indicates positive operational momentum and a clear trajectory towards profitability. Strategic initiatives like global infrastructure expansion, new product launches, and the DHL partnership position Cryoport for sustained long-term growth in a critical and expanding market. The current net loss is offset by the strong underlying business performance and future outlook, making it an attractive investment.

Keywords

Cryoport, CYRX, temperature-controlled supply chain, life sciences, cell and gene therapy, biologistics, biostorage, cryogenic systems, MVE Biological Solutions, financial results, Q3 2025, revenue guidance, adjusted EBITDA, clinical trials, BLA, MAA, DHL partnership